High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany

Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study

(2023) Kausik K. Ray et al.   ATHEROSCLEROSIS

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

(2023) Kausik K Ray et al.   Lancet Diabetes & Endocrinology

PCSK9 Inhibitors in Real-world Practice: Analysis of Data from 314 Patients and 2 Years of Experience in a Center of Preventive Cardiology

(2022) Tereza Altschmiedová et al.   Current Atherosclerosis Reports

Mechanisms of unusual response to lipid-lowering therapy: PCSK9 inhibition

(2022) Mingqi Ouyang et al.   CLINICA CHIMICA ACTA

Lipid lowering with inclisiran: a real-world single-centre experience

(2022) Pritpal Padam et al.   Open Heart

Inclisiran: First Approval

(2021) Yvette N. Lamb   DRUGS

Real-world utilization of bempedoic acid in an academic preventive cardiology practice

(2021) Bruce A. Warden et al.   Journal of Clinical Lipidology

Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies

(2021) Carlota Oleaga et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications

(2021) Xiao-dan Xia et al.   Frontiers in Cardiovascular Medicine

Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies

(2020) Julia Brandts et al.   CURRENT OPINION IN LIPIDOLOGY

Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9

(2020) Klaus-Dieter Schlüter et al.   Frontiers in Physiology

The emerging concept of “individualized cholesterol-lowering therapy”: A change in paradigm

(2019) Dieter Lütjohann et al.   PHARMACOLOGY & THERAPEUTICS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Inclisiran—New hope in the management of lipid disorders?

(2019) Krzysztof Dyrbuś et al.   Journal of Clinical Lipidology

Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic

(2018) Barak Zafrir et al.   Cardiovascular Therapeutics

Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Pre-Specified Secondary End Points in ORION 1

(2018) Kausik K. Ray et al.   CIRCULATION

Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab

(2018) Arman Qamar et al.   JAMA Cardiology

Statins and Their Effect on PCSK9—Impact and Clinical Relevance

(2016) Beth A. Taylor et al.   Current Atherosclerosis Reports

Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents

(2016) Paul M Ridker et al.   EUROPEAN HEART JOURNAL

Expanding the Evidence Base

(2015) Dan Atar et al.   AMERICAN JOURNAL OF THERAPEUTICS

Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients

(2015) Olivier Descamps et al.   ATHEROSCLEROSIS

Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials

(2015) A. Sahebkar et al.   DIABETES OBESITY & METABOLISM

PCSK9

(2014) Nabil G. Seidah et al.   CIRCULATION RESEARCH

Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events

(2014) S. Matthijs Boekholdt et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Anti-PCSK9 Monotherapy for Hypercholesterolemia

(2014) Michael J. Koren et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment

(2011) Hein A.W. van Onzenoort et al.   HYPERTENSION